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Abstract
Cervical cancer is one of the leading causes of cancer-related death in women in sub-Saharan Africa. Extensive evidence has
shown that cervical cancer and its precursor lesions are caused by Human papillomavirus (HPV) infection. Although the vast
majority of HPV infections are naturally resolved, failure to eradicate infected cells has been shown to promote viral
persistence and tumorigenesis. Furthermore, following neoplastic transformation, exposure of cervical epithelial cells to
inflammatory mediators either directly or via the systemic circulation may enhance progression of the disease. It is well
recognised that seminal plasma contains an abundance of inflammatory mediators, which are identified as regulators of
tumour growth. Here we investigated the role of seminal plasma in regulating neoplastic cervical epithelial cell growth and
tumorigenesis. Using HeLa cervical adenocarcinoma cells, we found that seminal plasma (SP) induced the expression of the
inflammatory enzymes, prostaglandin endoperoxide synthase (PTGS1 and PTGS2), cytokines interleukin (IL) -6, and -11 and
vascular endothelial growth factor-A(VEGF-A). To investigate the role of SP on tumour cell growth in vivo, we xenografted
HeLa cells subcutaneously into the dorsal flank of nude mice. Intra-peritoneal administration of SP rapidly and significantly
enhanced the tumour growth rate and size of HeLa cell xenografts in nude mice. As observed in vitro, we found that SP
induced expression of inflammatory PTGS enzymes, cytokines and VEGF-A in vivo. Furthermore we found that SP enhances
blood vessel size in HeLa cell xenografts. Finally we show that SP-induced cytokine production, VEGF-A expression and cell
proliferation are mediated via the induction of the inflammatory PTGS pathway.
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Introduction
At present, there are more than 273,000 deaths worldwide from
cervical cancer each year accounting for 9% of total cancer deaths
in women [1]. In sub-Saharan Africa, cervical cancer is one of the
leading causes of cancer related death in women [2]. Infection
with high risk HPV is the most common risk factor for the
development of cervical cancer, with HPV 16 accounting for at
least 50% of malignancies [3]. Furthermore, other factors
including a weakened immune system and sexually transmitted
infection by Chlamydia trachomatis and Neisseria gonorrhoeae
can contribute to the etiology of cervical cancer [4].
Persistent virus infection, such as that caused by HPV has been
associated with chronic inflammation and cancer [5]. A link between
high risk HPV infection of cervical epithelial cells and the prostaglandin
endoperoxide synthase (PTGS also called cyclooxygenase; COX)
pathway has been established [6]. These findings suggest that HPV-
mediated tumour growth may be regulated by inflammatory pathways.
However the detailed cellular and molecular mechanisms and
inflammatory pathways responsible for cervical cancer progression
following HPV infection remain to be fully determined.
Although simplistically regarded as an alteration in immune cell
recruitment to sites of injury and repair, inflammation involves
alterations to epithelial, vascular and immune cell function. These
are orchestrated by specific molecular pathways involving a host of
growth factors, cytokines, chemokines and lipid mediators, which
initiate tissue regeneration and repair mechanisms and alters the
function of the vasculature and the endothelium to enhance
angiogenesis, vascular permeability and the extravasation of
immune cells from the blood to the inflamed tissue [7]. The link
between chronic inflammation and cancer has been long
established [8,9]. Our laboratory and others have demonstrated
elevated expression of PTGS1, PTGS2, the E-series prostanoid
receptors PTGER2 and PTGER4 together with enhanced
biosynthesis and signaling of PGE2 in cervical carcinomas
[10,11,12,13]. These findings suggest an important regulatory
mechanism for this inflammatory axis in cervical cancers. This
pro-inflammatory pathway can be induced by a variety of stimuli,
including lipopolysaccharides (LPS), cytokines, growth factors and
tumour-promoting chemical carcinogens [14]. Moreover in
sexually active women, in the absence of barrier contraceptive,
the inflammatory environment can be further modulated by
mediators present in seminal fluid [15,16,17]. Seminal fluid is
comprised of a vast diversity of antigenically distinct molecules that
include cytokines, angiogenic factors, prostaglandins, proteases,
protein kinases, transporter proteins, structural molecules and
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immune response proteins [18,19]. In several species, seminal fluid
has been shown to interact with the epithelial lining of the
reproductive tract and activate the innate and adaptive immune
system [20,21]. This promotes the influx of immune cells such as
dendritic cells, granulocytes and leukocytes and activates and
expands inducible regulatory T cell populations to promote
immune tolerance and prepare the reproductive tract for
conception [22,23,24]. However, little is known of the effect of
seminal plasma (SP) on the neoplastic cervical epithelium of
sexually active women. SP can promote the release of matrix
metalloproteinases (MMPs) which can enhance metastases [25,26],
as well as promote the release of local pro-inflammatory mediators
such as IL-1ß and IL-8 to regulate the tumour microenvironment.
Furthermore, components of SP can enter into the endometrial
bed or the peritoneal bed as a result of hematogenous
dissemination or direct tissue perfusion through the anterior or
posterior vaginal fornix after sexual intercourse [27]. It is therefore
plausible that in addition to the direct regulation of cell surface
proteins by SP, repeated exposure of the cervico-vaginal interface
to seminal fluid could result in an alteration in the local levels of
inflammatory mediators which could enhance cervical tumorigen-
esis.
Here we investigated the impact of seminal plasma on
neoplastic cervical epithelial cell growth and tumorigenesis. Using
HeLa cervical adenocarcinoma cells, we found that seminal
plasma (SP) induced the expression of the inflammatory enzymes,
prostaglandin endoperoxide synthase (PTGS1 and PTGS2),
cytokines IL-6, IL-11 and the angiogenic factor VEGF-A in vitro.
We subsequently investigated the role of SP in inflammation-
induced tumorigenesis in vivo by xenografting HeLa cells
subcutaneously in the dorsal flank of nude mice. Following
engraftment, mice were injected with SP by intraperitoneal
injection three times weekly. Administration of SP rapidly and
significantly enhanced the tumour growth rate and size of HeLa
cell xenografts. As observed in vitro, we found that SP induced
expression of PTGS1, PTGS2 and the PG receptors PTGER1,
PTGER2 and PTGER4 as well as inflammatory cytokines IL-6
and IL-11 in vivo. Furthermore we found that SP enhanced the
expression of VEGF-A and blood vessel size in HeLa cell
xenografts. Finally we show a mechanism for the SP-induced IL-
6, IL-11, VEGF-A and HeLa cell proliferation in vitro via the
induction of the inflammatory PTGS pathway.
Methods
Ethics statement
Human Ethics. Ethics approval for the study was obtained
from the University of Cape Town Research Ethics Committee
(REC/REF: 152/99). Written informed consent was obtained
from all subjects before sample collection.
Animal Ethics. All mouse experiments were performed
according to protocols approved by the University of Cape
Town Animal Research Ethics Committee (approval no. REC/
REF:006/044).
Reagents
Culture medium, penicillin-streptomycin and fetal-calf serum
was purchased from Highveld Biological (PTY) Limited (Cape
Town, South Africa). PBS, BSA, Percoll and Tri-reagentH were
purchased from Sigma Chemical Company (Cape Town, South
Africa). CellTitre96 Aqueous One Solution Proliferation Reagent
was purchased from Promega Corp. (Madison, WI, USA). Ki-67
and CD31 antibodies were purchased from Vector Laboratories
(Peterborough, UK) and Abcam (Cambridge, UK) respectively.
Cell culture
Wild type HeLa-S3 cells were purchased from BioWhittaker
(Berkshire, UK) and were maintained in DMEM nutrient mixture
F-12 with Glutamax-1 and pyridoxine supplemented with 10%
fetal bovine serum and 1% penicillin-streptomycin (500 IU/ml
penicillin and 500 mg/ml streptomycin) at 37uC and 5% CO2 (v/
v).
Semen donors and preparation
Semen was obtained from 10 healthy males attending the
Andrology Laboratory of the Reproductive Medicine Unit at
Groote Schuur Hospital, Cape Town. Ejaculates were collected in
sterile specimen jars following voluntary self-masturbation. Days of
sexual abstinence prior to ejaculation were self-reported and
sample volume, sperm count, pH and viscosity were noted. All
samples were processed within 2–4 hours after collection. The ten
individual ejaculates were transported to the laboratory and were
pooled and overlayed on a 100-50% percoll gradient. Seminal
plasma (SP) was isolated from the pooled ejaculate by density
gradient centrifugation at 500 g for 20 min. The seminal plasma
was aliquoted and stored at 280uC until required. Prior to
injection, the seminal plasma was thawed on ice and diluted in
sterile filtered serum free medium to use at a concentration of
1:100 for in vitro studies and diluted in sterile filtered PBS to a
dilution of 1:500 for in vivo studies. Seminal fluid has been
reported to exert no effect on HeLa cell viability up to and
including a dilution of 1:50 [25].
Xenograft experiments
A suspension of 26106 HeLa cells in a total volume of 0.2 ml
PBS was injected subcutaneously into the right dorsal flank of MF-
1 nude mice. Following engraftment, the mice were assigned into
two treatment groups, Control (n = 8) and SP (n = 6). The mice
were injected three times weekly with 100 ml PBS or SP (1:500) via
intra-peritoneal injection for ten weeks. At the end of the study
animals were sacrificed and tumours excised. A portion of the
tumour was fixed in 0.2% paraformaldehyde for wax-embedding
and immunohistochemistry and the remainder used for RNA
extraction. The animals were maintained under sterile conditions
in individually vented cages.
Immunohistochemical analysis
Immunohistochemistry was performed on nude mouse xeno-
grafts (n = 5 control, n = 5 SP treated animals) using standard
techniques as previously described [28]. Following antigen
retrieval, sections were blocked in 5% normal goat serum (Ki-
67) or normal porcine serum (CD31) diluted in Tris-buffered
saline (TBS) with 5% BSA. Tissue sections were incubated with
mouse anti-human Ki-67 polyclonal antibody (1:200) or rabbit
anti mouse/human CD31 polyclonal antibody (1:250) overnight at
4uC. Control tissue was incubated with immunoglobulin (IgG)
from the host species. Subsequently sections were incubated with
goat anti-mouse biotinylated or porcine anti-rabbit biotinylated
antibodies (DAKO, Cambridgeshire, UK), followed by streptavi-
din-horse radish peroxidase complex (DAKO). Colour reaction
was developed with 393 diaminobenzidine (DAKO), and sections
were counterstained in haemotoxylin. The number of positively
stained cells for Ki-67 was quantified using standard stereological
techniques. Briefly, each section was examined using a 640
objective from a Leitz DMRB microscope (Leica Microsystems
Wetzlar, Germany) fitted with an automatic stage (Prior Scientific
Instruments Ltd, Cambridge, UK) using a live-feed camera (JVC-
KYF55B; Yokohama, Japan) and were analyzed using Image-Pro
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Plus 6.2 software (Media Cybernetics, Wokingham, Berkshire,
UK). A total of 20 randomized fields of view were examined and
counted from a total of five individual control and five individual
SP xenograft tumours. Data are expressed as mean number of
positively stained cells per tumour examined. Blood vessel size in
the xenografts (n = 5 Control, n = 5 SP treated animals) was
measured in sections that were stained with CD31 to highlight the
blood vessel perimeter. A total of 100 randomized fields of view
were examined for control and treated animal. Blood vessel
diameter was measured using Image-Pro Plus 6.2 software. Data
are represented as mean size of blood vessels per mm2 of tumour
examined.
Taqman quantitative RT-PCR
HeLa cell and xenograft RNA was extracted using Tri-reagent
(Qiagen, Crawley, UK) following the manufacture’s guidelines.
RNA samples were reverse transcribed using VILO (Invitrogen,
Paisley, UK). Quantitative RT-PCR was performed under
standard operating conditions using an ABI Prism 7500 (Applied
Biosystems, Warrington, UK), using sequence-specific primers and
6-carboxyfluoresceine-labelled probes as detailed in table 1.
Expression of PTGS1, PTGS2, PTGER receptors, IL-6, IL-11,
VEGF-A and Ki-67 were normalized to RNA loading for each
sample using the 18S ribosomal RNA as an internal standard.
Data were analysed and processed using Sequence Detector v1.6.3
(Applied Biosystems). Results are expressed relative to an
endogenous control of HeLa cell cDNA included in each
experiment or expressed as a fold increase determined by dividing
the relative expression of the treatment group by the relative
expression of the control group. Data are presented as mean 6
SEM.
Cell Proliferation
HeLa cells were seeded in 6 well plates at a density of 26105
cells per well in a final volume of 2 ml and allowed to propagate
overnight before serum starvation for 24 hours. Thereafter cells
were treated with SP (1:100) or vehicle for 6 hours and the RNA
subjected to real time RT-PCR analysis for Ki67 as described
above. To investigate the expression of Ki-67 protein in HeLa
cells, cells were seeded at a density of 56104 cells per well in a final
volume of 1 ml in 2 well-chamber slides and allowed to adhere for
24 hrs before serum starvation overnight. The next day, cells were
treated with SP (1:500) or vehicle for 24, 48 or 72 hrs. Following
treatment, cells were washed with PBS and fixed with 4%
paraformaldehyde (diluted in PBS) for 10 min. Thereafter, the
cells were subjected to two washes in TBS (50 mM Tris/HCl,
150 mM NaCl, pH 7.4) and blocked using 5% normal swine
serum diluted in TBS for 30 min at room temperature. Cells were
then incubated with the specific primary antibody for Ki-67
(1:200) at 4uC overnight. The following day, the cells were
incubated with 1:250 dilution of swine-anti-rabbit biotinylated
secondary antibody (DAKO, Cambridge, UK). The slides were
incubated with streptavidin peroxidase (1:1000) and detected with
393 diaminobenzidine (DAKO). Slides were counterstained with
haemotoxylin and the number of positively stained cells for Ki-67
quantified by stereologer using Image-Pro Plus 6.2 software as
described above. The effect of inhibition of PTGS enzymes on
HeLa cell proliferation was determined using the CellTitre96
Aqueous One Solution Proliferation Reagent (Promega Corp) as
per the manufacturer’s protocol. HeLa cells were seeded in 96-well
plates at a density of 3000 cells per well and allowed to propagate
overnight before serum starvation for 24 hrs. Thereafter cells were
treated with SP (1:100) or vehicle for 24, 48 and 72 hrs. Data are
presented as mean 6 SEM of four independent experiments.
Statistical Analysis
The data in this study was analyzed by t-test or one-way
ANOVA using Graph Pad Prism 4.0c (Graph Pad, San Diego,
CA). Where data are presented as fold increase, all statistical
analysis was performed on untransformed data prior to conversion
to fold increase.
Results
Upregulation of PTGS expression in HeLa cells in
response to treatment with seminal plasma
We investigated whether exposure of neoplastic cervical
epithelial cells to seminal plasma would induce expression of the
inflammatory prostaglandin endoperoxide synthase (PTGS) path-
way, which has been shown to promote tumorigenesis. HeLa
Table 1. Sequences of Taqman primers and probes for Real
Time (RT-PCR).
Target Gene Sequence of Primers and Probe (59-39)
PTGS-1 Forward primer TGTTCGGTGTCCAGTTCCAATA
PTGS-1 Reverse primer ACCTTGAAGGAGTCAGGCATGAG
PTGS-1 Probe (FAM) CGCAACCGCATTGCCATGGAGT
PTGS-2 Forward primer CCTTCCTCCTGTGCCTGATG
PTGS-2 Reverse primer ACAATCTCATTTGAATCAGGAAGCT
PTGS-2 Probe (FAM) TGCCCGACTCCCTTGGGTGTCA
PTGER1 Forward primer AGATGGTGGGCCAGCTTGT
PTGER1 Reverse primer GCCACCAACACCAGCATTG
PTGER1 Probe (FAM) CAGCAGATGCACGACACCACCATG
PTGER2 Forward primer GACCGCTTACCTGCAGCTGTAC
PTGER2 Reverse primer TGAAGTTGCAGGCGAGCA
PTGER2 Probe (FAM) CCACCCTGCTGCTGCTTCTCATTGTCT
PTGER3 Forward primer GACGGCCATTCAGCTTATGG
PTGER3 Reverse primer TTGAAGATCATTTTCAACATCATTATCA
PTGER3 Probe (FAM) CTGTCGGTCTGCTGGTCTCCGCTC
PTGER4 Forward primer ACGCCGCCTACTCCTACATG
PTGER4 Reverse primer AGAGGACGGTGGCGAGAAT
PTGER4 Probe (FAM) ACGCGGGCTTCAGCTCCTTCCT
IL-6 Forward primer GCCGCCCCACACAGACA
IL-6 Reverse primer CCGTCGAGGATGTACCGAAT
IL-6 Probe (FAM) CCACTCACCTCTTCAGAACGAATTGACAAAC
IL-11 Forward primer CCCAGTTACCCAAGCATCCA
IL-11 Reverse primer AGACAGAGAACAGGGAATTAAATGTGT
IL-11 Probe (FAM) CCCCAGCTCTCAGACAAATCGCCC
VEGF-A Forward primer TACCTCCACCATGCCAAGTG
VEGF-A Reverse primer TAGCTGCGCTGATAGACATCCA
VEGF-A Probe (FAM) ACTTCGTGATGATTCTGCCCTCCTCCTT
Ki-67 Forward primer GGACTTGCACGACTAA
Ki-67 Reverse primer CCGTACGTCAATTGAC
Ki-67 Probe (FAM) TTCGAACTGATCAT
18 s Forward primer CGGCTACCACATCCAAGGAA
18 s Reverse primer GCTGGAATTACCGCGGCT
18 s Probe (FAM) TGCTGGCACCAGACTTGCCCTC
doi:10.1371/journal.pone.0033848.t001
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cervical adenocarcinoma cells were treated with 1:100 dilution of
SP or vehicle (PBS) for 6 hours and the mRNA expression of
PTGS1 and PTGS2 was determined by quantitative RT-PCR
analysis. We found that SP significantly elevated expression of
PTGS1 (Figure 1A; 7.362.7 fold increase compared to vehicle
treatment; P,0.01) and PTGS2 (Figure 1B; 3.460.5-fold increase
compared to vehicle treatment; P,0.01).
Seminal plasma induces expression of pro-inflammatory
cytokines IL-6, IL-11 and pro-angiogenic factor VEGF-A in
HeLa cells
Having established that SP induces the expression of PTGS1
and PTGS2, we next investigated the effect of SP on the
expression of potent pro-inflammatory cytokines IL-6 and IL-11
and the pro-angiogenic factor VEGF-A by quantitative RT-PCR
analysis. Treatment of HeLa cells with SP (1:100) for 6 hrs
significantly increased the expression of IL-6 (Figure 2A, 19.862.3
fold; P,0.001), IL-11 (Figure 2B, 28.863.8 fold; P,0.001) and
VEGF-A (Figure 2C, 2.960.9 fold; P,0.05) mRNA compared to
vehicle treatment.
Seminal plasma enhances growth and weight of
xenograft tumours in vivo
Components of SP, including prostaglandins, can enter into the
endometrial bed or the peritoneal bed as a result of hematogenous
dissemination or direct tissue perfusion through the anterior or
posterior vaginal fornix after sexual intercourse [27]. We
investigated whether SP could enhance tumorigenesis in vivo via
the elevation of inflammatory mediators present systemically. We
Figure 1. Upregulation of PTGS expression in HeLa cells in
response to treatment with seminal plasma. (A) PTGS1 and (B)
PTGS2 mRNA expression was measured by quantitative RT-PCR analysis
and is significantly increased by SP (1:100) as compared to vehicle (PBS)
control, (both P,0.01**). Data are represented as mean 6 SEM from 4
independent experiments.
doi:10.1371/journal.pone.0033848.g001
Figure 2. Increased expression of pro-inflammatory and pro-
angiogenic mediators IL-6, IL-11 and VEGF-A in HeLa cells in
response to treatment with seminal plasma. (A) IL-6, (B) IL-11 and
(C) VEGF-A mRNA expression as determined by quantitative RT-PCR
analysis are significantly increased in HeLa cells treated with SP (1:100)
in comparison to the vehicle (PBS) control treatment group, (*P,0.05,
P,0.001***). Data are represented as mean 6 SEM from 6 independent
experiments.
doi:10.1371/journal.pone.0033848.g002
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engrafted HeLa cells subcutaneously into the dorsal flank of MF-1
nude mice. Following engraftment, animals were administered SP
(1:500 dilution) or PBS (control group) three times a week via
intra-peritoneal injection and tumour growth was measured over a
10 week period. We found a significant divergence in the growth of
tumours in animals administered with SP compared with control,
which was significant at 10 weeks (Figure 3A; P,0.05). Upon
excising the tumours at the end of the 10 week treatment period,
the tumours removed from the SP treated group also weighed
significantly more than the control group confirming the SP-
induced increase in tumorigenesis (Figure 3B; P,0.05). Having
ascertained a significant increase in tumour size and weight in
response to SP administration, we next confirmed that the
enhanced tumour size and weight was due to induction of tumour
cell proliferation by SP. Quantitative RT-PCR analysis for the
proliferation marker Ki-67 revealed a 7.562.2 fold elevation in
proliferation rate in xenograft tumours from SP treated mice
compared with control mice (Figure 3C; P,0.05). This increase in
proliferation index of xenograft tumours in mice treated with SP
was further confirmed by immunohistochemistry with antisera for
Ki-67 (indicated by the increased brown staining in SP treated
tumours, arrowed in Figure 3D) and by quantitative stereology,
Figure 3. Seminal plasma enhances growth and weight of xenograft tumours in vivo. The effects of SP on tumour growth and tumour
weight. MF-1 nude mice were engrafted with HeLa cells and treated with SP (n = 6) or vehicle (PBS) controls (n = 8). (A) Tumour size in the nude mice
xenografts is significantly different after 10 weeks of SP injections in comparison to PBS treated mice (P,0.05*). (B) The weight of the tumours was
determined at the end of the 10 week experimental period. Mice injected with SP displayed a significantly increased tumour weight in comparison to
the control group (P,0.05*). (C) Ki-67 mRNA expression was measured by quantitative RT-PCR analysis and is significantly increased by SP (1:500) as
compared to the controls, (P,0.05*). (D) Immunohistochemical staining of Ki67 in SP-treated and control tumours from HeLa cell xenografts (n = 5
per group). (E) Number of positively stained cells for Ki67 was quantified and is significantly increased when treated with SP (1:500) in comparison to
the vehicle control treatment group (P,0.05*). Data are represented as mean 6 SEM.
doi:10.1371/journal.pone.0033848.g003
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which displayed 6664 percent Ki-67 positive immunoreactivity in
SP treated tumours in comparison to 3569 percent in control
tumours (Figure 3E; P,0.05).
Upregulation of PTGS and PTGER expression in xenograft
tumours in response to treatment with seminal plasma
We investigated whether expression of the inflammatory PTGS-
PTGER pathway was elevated in the xenograft tumours arising
from SP-treated animals by quantitative RT-PCR analysis. We
found that xenograft tumours from mice treated with SP had
significantly elevated expression of PTGS1 (Figure 4A) and
PTGS2 (Figure 4B) mRNA compared to controls (3.160.1 fold;
P,0.01 and 6.260.2 fold; P,0.001 for SP vs control for PTGS1
and PTGS2 respectively). Previous in vitro studies from our
laboratory have shown that induction of PTGS enzymes
coincidently upregulate prostaglandin receptor expression and
signalling in vitro [29,30]. Hence, we investigated the effect of SP
treatment on expression of prostaglandin receptors in xenograft
tumours. Administration of SP induced the expression of
PTGER1 (Figure 4C), PTGER2 (Figure 4D) and PTGER4
(Figure 4F) mRNA in the SP-treated animals compared to the
Figure 4. Upregulation of PTGS and PTGER expression in xenograft tumours in response to treatment with seminal plasma. (A)
PTGS1 and (B) PTGS2 mRNA expression was measured by quantitative RT-PCR and is significantly increased by SP (1:500) as compared to the vehicle
(PBS) control, (P,0.01** and P,0.001***) respectively. (C) PTGER1 (P,0.01**), (D) PTGER2 (P,0.05*), (E) PTGER3 (ns) and (F) PTGER4 (P,0.05*)
mRNA expression levels of the 4 different subtypes of the PGE2 receptors as determined by quantitative RT-PCR analysis. Data are represented as
mean 6 SEM from SP (n = 6) or vehicle controls (n = 8).
doi:10.1371/journal.pone.0033848.g004
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control group (3.260.3 fold, P,0.01; 2.960.3 fold, P,0.05;
3.160.3 fold, P,0.05 for SP vs control for PTGER1, PTGER2
and PTGER4 respectively), but had no significant effect on
expression of PTGER3 mRNA (Figure 4E).
Increased expression of pro-inflammatory mediators IL-6
and IL-11 and pro-angiogenic factor VEGF-A in xenograft
tumours in response to treatment with seminal plasma
Inflammatory effectors, including growth factors and prosta-
glandins are known to regulate the tumour microenvironment by
inducing pro-inflammatory cytokines and potent proangiogenic
factors in order to mobilize immune cells and promote
angiogenesis and vascular permeability [8]. We next investigated
the expression of potent pro-inflammatory cytokines and angio-
genic factors with known roles in tumour development in the
tumour xenografts. Quantitative RT-PCR analysis showed a
significant increase in expression of IL-6 (Figure 5A) and IL-11
(Figure 5B) mRNA expression in tumour xenografts in SP-treated
animals compared to the control group (2.760.2 fold, P,0.01 and
2.660.1 fold, P,0.05 for SP vs control for IL-6 and IL-11,
respectively). Furthermore, we found a significant increase in
VEGF-A mRNA expression in xenograft tumours in mice injected
with SP in comparison to the control group (4.660.2 fold;
Figure 5C; P,0.001).
Blood vessel size is increased in nude mouse xenografts
treated with seminal plasma
Since we identified that the HeLa cell xenograft tumours from
mice administered SP had elevated VEGF-A expression, we
investigated whether these tumours also displayed a more
developed vasculature relative to tumours collected from mice
that were treated with vehicle. We performed immunohistochem-
istry on HeLa cell xenograft tumours for the endothelial cell
marker CD31 and quantified blood vessel size by stereology
(Figure 6). We found that that SP treatment significantly increased
blood vessel size from 247619 mm2 to 388622 mm2 in xenograft
tumours (1.760.1 fold for SP versus control group respectively;
P,0.01). These data suggest that the enhanced tumour growth
observed in xenografts arising from mice injected with SP was due
to an increase in the capacity of blood vessels to supply the tumour
with nutrients and oxygen.
Seminal plasma induction of IL-6, IL-11 and VEGF-A is
mediated via the inflammatory PTGS pathway
We investigated whether SP-mediated IL-6, IL-11 and VEGF-A
expression in vitro is mediated via the induction of the
inflammatory PTGS pathway. HeLa cells were treated with
1:100 dilution of SP (black bar) or vehicle (white bar) for 6 hours in
the absence or presence of the selective PTGS1 inhibitor SC560 or
selective PTGS2 inhibitor NS398 (dark grey bar) and IL-6, IL-11
and VEGF-A mRNA expression investigated by quantitative real
time RT-PCR analysis. We found that co-treatment of HeLa cells
with SP and the selective PTGS1 inhibitor SC560 significantly
reduced IL-11 (but not IL-6 or VEGF-A) mRNA expression (black
bar) compared with vehicle-treated cells (Figure 7B; white bar;
P,0.05). By contrast we found that co-treatment of HeLa cells
with SP and the selective PTGS2 inhibitor NS398 (dark grey bar;
P,0.05) completely abolished SP-mediated IL-6 and VEGF-A
mRNA expression (Figure 7A and 7C; black bar) to the levels
observed in vehicle treated cells (white bar). However, co-
treatment of cells with SP and NS398 had no significant effect
on SP-mediated IL-11 expression (Figure 7B). Furthermore,
treatment of HeLa cells with SC560 or NS398 alone had
negligible effect on basal expression of IL-6, IL-11 or VEGF-A
mRNA expression (light grey bar).
Seminal plasma enhances cellular proliferation and
cellular growth in HeLa cells via the PTGS2-PG pathway
Finally we investigated a potential mechanism for the SP-
induced growth and proliferation of neoplastic cervical epithelial
cells in vitro. HeLa cells were treated with SP (1:100) or vehicle for
6 hours and the RNA subjected to quantitative real time PCR for
the proliferation marker Ki-67. We found that SP significantly
increased the expression of Ki-67 mRNA when compared to the
Figure 5. Increased expression of pro-inflammatory cytokines
IL-6 and IL-11 and pro-angiogenic factor VEGF-A in xenograft
tumours in response to treatment with seminal plasma. (A) IL-6
(P,0.01**), (B) IL-11 (P,0.05*) and (C) VEGF-A (P,0.001***) mRNA
expression as determined by quantitative RT-PCR are significantly
increased in nude mice xenograft tumours administered with SP (1:500)
in comparison to the vehicle (PBS) control treatment group. Data are
represented as mean 6 SEM SP (n = 6) or vehicle (PBS) controls (n = 8).
doi:10.1371/journal.pone.0033848.g005
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vehicle control (Figure 8A; 3.660.9 fold, P,0.05). We confirmed
the increase in Ki-67 expression in SP-treated HeLa cells by
immunohistochemistry and quantitative stereology. Cells were
treated with SP (1:100) or vehicle for 24, 48 or 72 hours. We found
a significant increase in Ki-67 immunoreactivity at all time points
investigated in response to SP (1:100) stimulation (Figure 8B). In
order to determine a mechanism for the enhanced xenograft
tumour growth rate in vivo, we investigated whether SP-mediated
HeLa cell proliferation was mediated via the inflammatory PTGS
pathway. HeLa cells were treated with 1:100 dilution of SP (black
bar) or vehicle (white bar) for 72 hours in the absence or presence
of the selective PTGS1 inhibitor SC560 or selective PTGS2
inhibitor NS398 (dark grey bar, Figure 8C and 8D, respectively).
We found that although co-treatment of HeLa cells with SP and
the selective PTGS1 inhibitor marginally reduced cellular
proliferation (Figure 8C, dark grey bar), the reduction was not
statistically significant. However, co-treatment of cells with SP and
the selective PTGS2 inhibitor NS398 completely abolished the SP-
mediated increase in cellular proliferation (Figure 8D, dark grey
bar; P,0.05). Incubation of HeLa cells with inhibitor alone
(Figure 8C and 8D, light grey bar) had no significant effect on
basal cell proliferation.
Discussion
A functional relationship between inflammation and cancer has
been long established with Rudolf Virchow hypothesizing as early
as 1863 that the beginnings of cancer originated from chronic sites
of inflammation [8]. Cancer of the cervix remains the most prolific
female cancer in developing countries with a notable decline in
mortality rates in Western countries being ascribed to successful
screening programmes and vaccine development [31,32].
Although HPV infection of the cervical epithelium is well regarded
as the main cause of cervical cancer, it takes on average 10–15
years for the development of invasive disease. These observations
have led to the hypothesis that alternative biological cues and
causative factors in addition to persistent HPV infection are
required for the transition of precursor lesions to cervical cancer
[33,34]. Although intercourse with multiple sexual partners has
been implicated in the etiology of cervical cancer, the impact of
seminal fluid on the neoplastic cervical epithelium and its role in
regulating disease progression has yet to be fully investigated.
Figure 7. Seminal plasma regulates IL-6, IL-11 and VEGF-A
mRNA expression via the inflammatory PTGS pathway. Quan-
titative RT-PCR analysis of IL-6 (A), IL-11 (B) and VEGF-A (C) expression.
HeLa cells were treated for 6 hours with vehicle (white bars), inhibitor
alone (light grey bars), SP (1:100; black bars) or SP and inhibitor (dark
grey bars). (P,0.05*) Data are represented as mean 6 SEM from 4
independent experiments.
doi:10.1371/journal.pone.0033848.g007
Figure 6. Blood vessel diameter is increased in nude mouse
xenografts treated with seminal plasma. Blood vessel size as
determined by immunohistochemistry (representative images shown
for control and SP-treated animals) and quantitative stereology
performed on SP-treated and vehicle control (n = 5 per group)
xenograft tumours stained for the endothelial cell marker CD31. The
diameter of blood vessels was significantly increased xenograft tumours
from animals administered with SP (1:500) in comparison to the control
treatment group (P,0.05*).
doi:10.1371/journal.pone.0033848.g006
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It has recently been shown that seminal fluid induces an
inflammatory response in the cervix in humans after coitus,
characterised by the influx of leukocytes and dendritic cells into
the epithelium and stromal compartments and an accompanying
increase in inflammatory cytokines such as IL-6 and IL-8 [24]. In
the present study we show that direct exposure of neoplastic
cervical epithelial cells to SP in vitro can increase the expression of
both PTGS1 and PTGS2. We and others have previously shown
this pro-inflammatory PTGS-prostaglandin pathway to be up-
regulated in cervical cancer [10,11,12,13]. Elevated biosynthesis of
prostaglandins as a consequence of elevated PTGS enzyme
expression is a critical step in initiating inflammation and the
tissue remodeling associated with inflammation and cancer [7].
PG biosynthesis and signaling has been shown to enhance
tumorigenesis in human cancers [35,36]. The induction of this
pathway directly by SP suggests that in sexually active women,
repeated exposure of neoplastic cervical epithelial cells to SP can
potentially exacerbate the inflammatory actions of this pathway
and enhance disease progression.
Inflammatory effectors, including growth factors and prosta-
glandins are known to regulate the tumour microenvironment by
inducing pro-inflammatory cytokines/chemokines to modulate
neutrophil infiltration into tumours [37] and potentially alter
vascular permeability [38,39]. In our study, we show that in
addition to the PTGS-PG pathway, direct SP stimulation of HeLa
cells can enhance the expression of pro-inflammatory cytokines IL-
6 and IL-11 and the pro-angiogenic factor VEGF-A. These
mediators are involved in many regulatory roles but their
increased expression has been associated with several reproductive
tract cancers, including endometrial cancer, ovarian cell carcino-
ma and squamous cell carcinoma of the uterine cervix
[40,41,42,43,44,45]. The induced expression of these effector
molecules in neoplastic cervical epithelial cells by direct stimula-
tion with SP suggests that repeated exposure of the cervix to
seminal fluid in the absence of barrier contraception could
exacerbate tumour-associated inflammation and could enhance
disease progression.
In addition to direct exposure of the epithelial layer surrounding
the anterior and posterior vaginal fornix, ecto- and endocervix to
seminal fluid during intercourse, direct absorption of components
of SP can enter into the endometrial or peritoneal bed. The
intravaginal absorption of components of SP have been rigorously
debated [46], however vaginal absorption of molecules is widely
regarded as a potential means of drug delivery in women.
Absorption may occur as a result of hematogenous dissemination
or direct tissue perfusion through the anterior or posterior vaginal
fornix [27]. Although it is likely that the concentrations of
inflammatory mediators in SP in the recipient woman after
intercourse would be orders of magnitude lower than that found in
semen, concentrations of inflammatory mediators would never-
Figure 8. Seminal plasma enhances cellular proliferation and
cellular growth in HeLa cells via the PTGS2 pathway. The effects
of SP on cell proliferation and cell growth. (A) Ki-67 mRNA expression
was measured by quantitative RT-PCR analysis and is significantly
increased by SP (1:100) following treatment for 6 hrs in comparison to
the vehicle control (P,0.05*). (B) Quantitative stereology and
immunohistochemistry for Ki-67 on HeLa cells treated with SP (1:100)
for 24, 48 and 72 hrs. The number of positively stained cells were
quantified and was shown to be significantly increased in comparison
to the vehicle treatment groups, (P,0.05* and P,0.01 respectively). (C)
Cellular proliferation on HeLa cells treated for 72 hours with vehicle
(white bar), SC560 inhibitor alone (light grey bar), SP (1:100; black bar)
or SP and SC560 (dark grey bar). (D) Cellular proliferation on HeLa cells
treated for 72 hours with vehicle (white bar), NS398 inhibitor alone
(light grey bar), SP (1:100; black bar) or SP and NS398 (dark grey bar).
Cellular proliferation was determined as described in the methods
(P,0.05*). Data are represented as mean 6 SEM from 4 independent
experiments.
doi:10.1371/journal.pone.0033848.g008
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theless be greater in sexually active women and could impact in
situ on tumour growth.
In order to test whether raised systemic levels of inflammatory
mediators present in SP could enhance the growth rate of
neoplastic cervical epithelial cells and hence enhance tumour
progression, we used a nude mouse model system. We engrafted
HeLa cells subcutaneously into the dorsal flank of nude mice.
Following engraftment, animals were divided randomly into two
groups and administered seminal plasma or vehicle control via
intra-peritoneal injection. We used a five-fold lower concentration
of seminal plasma for the in vivo study and used an intra-
peritoneal route of administration to simulate the lower levels of
inflammatory mediators which would impact on neoplastic
cervical cell function in vivo, following diffusion into the
endometrial or peritoneal bed, compared with direct stimulation
of cells present in the endocervix at intercourse as discussed earlier
in our study. We found that HeLa cell xenografts in mice
administered SP grew at an accelerated rate resulting in tumours
of approximately twice the size and weight compared with
controls. These observations are similar to those of Liu and
colleagues, who recently showed that HeLa cells pre-treated with
seminal plasma and engrafted into nude mice grew at an
accelerated rate compared with control cells [47]. We investigated
whether the increase in tumour growth was due to cellular
proliferation of the engrafted HeLa cells. Quantitative real time
RT-PCR analysis and immunohistochemistry for the proliferation
marker Ki67 confirmed that the increased size, weight and growth
rate for xenografts from SP treated animals was due to accelerated
rate of HeLa cell proliferation. Coincident with the enhanced
tumour growth rate and size, we found an increase in expression of
components of the PTGS-PG pathway. As observed for our in
vitro studies, we found that SP enhanced the expression of the
inflammatory PTGS1 and PTGS2 enzymes and also elevated
expression of the E-series prostaglandin receptors PTGER1,
PTGER2 and PTGER4. We have previously shown that PTGS1,
PTGS2, PTGER2 and PTGER4 are elevated in cervical cancers
[11].
Our present study also shows that intra-peritoneal administra-
tion of SP can dramatically elevate the expression of pro-
inflammatory cytokines IL-6 and IL-11 in HeLa cell xenograft
tumours. Although the molecular mechanism whereby SP
regulates these cytokines is unclear, recent studies confirm that
SP can enhance expression of a host of cytokines, including IL-6,
IL-10 and monocyte chemoattractant protein-1 (MCP-1) in
cervical and vaginal epithelial cells vitro [48,49,50]. Expression
and production of inflammatory cytokines, including IL-6, are
elevated in carcinoma of the cervix, where they act as autocrine
growth factors to regulate the inflammatory response via induction
of the PTGS2-PGE2 signal transduction pathway [40,51]. This is
further supported by studies in mammals that show that seminal
plasma possesses the ability to interact with cervical and uterine
epithelial cells and trigger the release of pro-inflammatory
cytokines such as IL-6 which in turn induces local cellular and
molecular changes and immune cell recruitment which can
promote an inflammatory response [24,50,52]. Therefore, SP
can be deemed as a regulator of pro-inflammatory cytokines that
in turn contributes to controlling immune cell function and
inflammation, which can promote tumour progression.
In order for sustained tumour growth, an enhanced blood
supply is needed for the provision of necessary nutrients and
oxygen. Similar to our observation in vitro, we have shown that
seminal plasma significantly induced expression of the potent
angiogenic factor VEGF-A in xenograft tumours in vivo and
enhances blood vessel size. We believe that the larger vessel size
would permit greater delivery of oxygen and nutrients into the
tumour and facilitate more rapid growth thus leading to larger
xenograft tumours in SP treated animals in comparison to the
control treatment group. Indeed several studies have previously
shown that VEGF-A influences vessel size and therefore has an
impact on the angiogenesis in cervical cancer [53,54]. CD31
expression, as a marker of angiogenesis has been correlated with
microvessel density and metastases in numerous solid tumours,
including carcinomas of breast, lung and prostate [55,56,57,58]. A
recent study performed by Mazibrada and colleagues showed that
sections of invasive cervical cancer have significantly more CD31
expression in comparison to normal tissues [59]. The mechanisms
whereby SP enhances blood vessel size in vivo is unclear, however
we have shown in vitro that VEGF-A expression is regulated by
the PG pathway. We have previously demonstrated that PGE2 and
seminal plasma (1:500 dilution) can regulate VEGF-A expression
in HeLa cells in vitro via PTGER4-mediated activation of the
epidermal growth factor receptor and extracellular signal-regulat-
ed kinase pathways [16]. It is therefore likely that the increased
expression of VEGF-A induced by SP in HeLa cell xenografts
could alter vascular function and that this could likely be mediated
by PGE2 present in the SP via the elevated PTGER receptors in
the SP-treated xenografts. Furthermore, our data using selective
inhibition of PTGS enzyme activity confirm that PTGS-PG
pathway is central to regulating SP-mediated inflammatory and
angiogenic gene expression. These results are consistent with our
previous finding using a HeLa TeToff system for inducible
expression of PTGS1, where we demonstrated the molecular
mechanism for regulation of prostaglandin receptors and angio-
genic factors in HeLa cells by PTGS1, via the induction of PTGS2
and biosynthesis of PGE2 [12]. Although infiltrating immune cells
into tumours have been associated with angiogenesis [60], we did
not observe any differences in immune cell infiltrate between the
control or SP-treated animals, so it is unlikely that the alterations
in vascular size we observed in the present study are due to
immune cell infiltration.
To investigate whether SP directly impacted on cellular
proliferation, we treated HeLa cells with SP in vitro. We found
that SP significantly enhanced the expression of the proliferation
marker Ki67 in HeLa cells and increased cellular proliferation.
Furthermore we found that the SP-mediated increase in HeLa cell
proliferation was mediated by PTGS2, since treatment of cells
with the PTGS2 inhibitor NS398, but not the selective PTGS1
inhibitor SC560, abolished the SP-mediated increase in cellular
proliferation.
Seminal plasma is known to contain many inflammatory agents
such as prostaglandins, transforming growth factor-ß (TGF-ß), and
glycoprotein signalling molecules including cytokines and growth
factors [21]. These molecules are independently thought to induce
cellular and molecular changes in the cervical epithelium by
binding to specific target cells in the female reproductive tract,
thus modulating gene expression, cellular composition and
structure and function of local tissue via cytokine synthesis as well
as by release of other autocrine and paracrine factors [61]. In our
study we have not attempted to isolate the precise signaling
molecules in the SP responsible for orchestrating the effects we
observed in vitro and in vivo. It is likely that the net effect we
observe in relation to cervical cancer cell growth and inflammation
is a result of the integration of all signalling inputs into HeLa cells
in response to SP.
Conclusions
Our study has demonstrated that SP can mediate an
inflammatory response by upregulating the expression of pro-
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inflammatory enzymes PTGS1 and PTGS2, pro-inflammatory
cytokines IL-6 and IL-11 and the proangiogenic factor VEGF-A in
vitro and in nude mice in vivo. Furthermore we have
demonstrated that a raised systemic inflammatory response
simulated by intra-peritoneal administration of SP can enhance
the growth rate and size of HeLa cell xenograft tumours in nude
mice. Coincident with the enhanced growth rate in SP-treated
xenograft tumours, we found a significant alteration in the size of
the blood vessels supporting the SP-treated xenograft tumours.
These findings indicate gross tissue remodelling events in these
tumours in response to SP to facilitate greater nutrient supply to
support the enhanced growth rate. Finally we show in vitro, that
SP induces IL-6, IL-11 and VEGF-A expression and promotes
HeLa cell proliferation via induction of the inflammatory PTGS
pathway. Taken together our data strongly support a role for SP in
enhancing cervical tumorigenesis in sexually active women via the
induction of inflammatory pathways.
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